First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002 (also known as NAN-101) for the treatment of congestive heart failure (CHF).
from Breaking World Pharma News https://ift.tt/mvH2uec
Comments
Post a Comment